A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT07005128
Trial Phases:	Phase III	Protocol IDs:	20240178 (primary) NCI-2025-06345
Eligibility:	18 - 99 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Amgen, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT07005128

Summary

The main objective of the study is to compare the efficacy of tarlatamab in combination
with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin
and etoposide on prolonging overall survival (OS).

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.